Title Image


Home  /  Geneva-related   /  MMV launches the COVID Box to stimulate new drug research

MMV launches the COVID Box to stimulate new drug research

MMV contributes to the global hunt for new therapies for the SARS-CoV-2 virus with the launch of the COVID Box. The aim is to catalyse the discovery of drugs for COVID-19 disease by providing researchers with an initial set of 80 marketed drugs or compounds in development with known or predicted activity against the coronavirus SARS-CoV-2. An additional 80 compounds will be added to the Box in the coming weeks.

In the space of a few months, COVID-19 has infected almost 7 million people and caused over 400,000 deaths, placing unprecedented pressure on healthcare systems and case management.”The spread of COVID-19 threatens to compromise control efforts for other infectious diseases like malaria by jeopardising access to life-saving antimalarial medicines and emergency care,” says Dr David Reddy, MMV’s CEO. “This pandemic calls for a united front, particularly with regard to research and development of new medicines. MMV has assembled the open access COVID Box to help spearhead such a collaborative response.”